Abbvie Inc SEC Filings

Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.

AbbVie Inc. (ABBV) Form 144 notice: An insider proposes to sell 62,755 shares of common stock through Morgan Stanley Smith Barney LLC on 08/22/2025. The shares were acquired the same day via a stock option exercise and paid for in cash. The filing lists an aggregate market value for the proposed sale of $13,231,264.20 and reports 1,766,558,253 shares outstanding for the class. The filer also reported four prior common-stock sales in August 2025 by Richard A. Gonzalez: 61,500 shares on 08/01/2025 (gross proceeds $12,043,268.25), 35,120 shares and 91,600 shares on 08/04/2025 (gross proceeds $6,828,296.22 and $19,208,000.00 respectively), and 90,000 shares on 08/21/2025 (gross proceeds $18,993,947.76). The filer certifies no undisclosed material adverse information and acknowledges legal penalties for false statements.

AbbVie insider sale notice: This Form 144 shows that Richard A. Gonzalez intends to sell 90,000 AbbVie (ABBV) common shares through Morgan Stanley Smith Barney on 08/21/2025 with an aggregate market value of $18,993,947.76. The filing reports Abbies outstanding shares as 1,766,558,253, so the planned sale represents a small fraction of total shares. The 90,000 shares were acquired the same day, 08/21/2025, by stock option exercise and paid for in cash.

The filing also discloses recent insider sales by Richard A. Gonzalez during the past three months: 61,500 shares sold 08/01/2025 for $12,043,268.25; 35,120 shares sold 08/04/2025 for $6,828,296.22; and 91,600 shares sold 08/04/2025 for $19,208,000. The notice includes the standard insider representation that no undisclosed material adverse information is known.

Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie Inc. (ABBV), reported transactions on 08/12/2025 showing she exercised employee stock options and simultaneously sold the resulting shares. She acquired 42,370 shares through exercise at a reported exercise price of $54.86 per share and sold 42,370 shares the same day at a weighted-average sale price of $198.42 per share. Following these transactions, her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares. The Form 4 notes 2,647 shares are held in an AbbVie savings program and 3,873 shares are held by her spouse (for which she disclaims beneficial ownership). The transactions were reported by an attorney-in-fact and the filing includes an explanatory footnote that the sale prices reported represent a range of prices between $198.34 and $198.58.

AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.

The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.

AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.

The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.